| Michael A Kueber Jr, MD | |
|
450 Williams Way, Moab, UT 84532-2185 | |
| (435) 719-3510 | |
| Not Available |
| Full Name | Michael A Kueber Jr |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 450 Williams Way, Moab, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578858171 | NPI | - | NPPES |
| ENROLLED | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 55346 (Minnesota) | Secondary |
| 207P00000X | Emergency Medicine | P9892 (Texas) | Secondary |
| 207P00000X | Emergency Medicine | 10495615-1205 (Utah) | Primary |
| Entity Name | Colorado West Healthcare System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497723407 PECOS PAC ID: 3971491887 Enrollment ID: O20040310000712 |
News Archive
A poster from Sunnybrook Health Sciences Centre entitled "Innovative Technology Conserves Resources and Generates Savings: A Case Study from the Sunnybrook Regional Processing Centre" was voted Best Overall Poster by delegates attending the 2010 CADTH Symposium in Halifax, Nova Scotia.
The German Institute for Quality and Efficiency in Health Care already assessed the added benefit of ipilimumab in advanced melanoma in 2012. A considerable added benefit was found for patients who had already received previous treatment. In the new dossier compiled by the drug manufacturer, the drug was now compared with the appropriate comparator therapy dacarbazine specified by the Federal Joint Committee (G-BA) also for non-pretreated patients.
At a time when drug overdoses are becoming more prevalent and lethal, a new report provides a snapshot of regional illicit drug use and, for the first time, highlights the complexity of detecting and treating patients at hospital emergency departments for a severe drug-related event.
The Food and Drug Administration (FDA) today announced the addition of new risk information to the health professional labeling for Zelnorm (tegaserod maleate). Zelnorm is a prescription medication for the short-term treatment of women with irritable bowel syndrome (IBS) whose primary bowel symptom is constipation.
› Verified 6 days ago
| Entity Name | Telluride Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508807694 PECOS PAC ID: 2961496807 Enrollment ID: O20040413000816 |
News Archive
A poster from Sunnybrook Health Sciences Centre entitled "Innovative Technology Conserves Resources and Generates Savings: A Case Study from the Sunnybrook Regional Processing Centre" was voted Best Overall Poster by delegates attending the 2010 CADTH Symposium in Halifax, Nova Scotia.
The German Institute for Quality and Efficiency in Health Care already assessed the added benefit of ipilimumab in advanced melanoma in 2012. A considerable added benefit was found for patients who had already received previous treatment. In the new dossier compiled by the drug manufacturer, the drug was now compared with the appropriate comparator therapy dacarbazine specified by the Federal Joint Committee (G-BA) also for non-pretreated patients.
At a time when drug overdoses are becoming more prevalent and lethal, a new report provides a snapshot of regional illicit drug use and, for the first time, highlights the complexity of detecting and treating patients at hospital emergency departments for a severe drug-related event.
The Food and Drug Administration (FDA) today announced the addition of new risk information to the health professional labeling for Zelnorm (tegaserod maleate). Zelnorm is a prescription medication for the short-term treatment of women with irritable bowel syndrome (IBS) whose primary bowel symptom is constipation.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael A Kueber Jr, MD 2280 Rock Valley Rd, Grand Junction, CO 81507-1639 Ph: () - | Michael A Kueber Jr, MD 450 Williams Way, Moab, UT 84532-2185 Ph: (435) 719-3510 |
News Archive
A poster from Sunnybrook Health Sciences Centre entitled "Innovative Technology Conserves Resources and Generates Savings: A Case Study from the Sunnybrook Regional Processing Centre" was voted Best Overall Poster by delegates attending the 2010 CADTH Symposium in Halifax, Nova Scotia.
The German Institute for Quality and Efficiency in Health Care already assessed the added benefit of ipilimumab in advanced melanoma in 2012. A considerable added benefit was found for patients who had already received previous treatment. In the new dossier compiled by the drug manufacturer, the drug was now compared with the appropriate comparator therapy dacarbazine specified by the Federal Joint Committee (G-BA) also for non-pretreated patients.
At a time when drug overdoses are becoming more prevalent and lethal, a new report provides a snapshot of regional illicit drug use and, for the first time, highlights the complexity of detecting and treating patients at hospital emergency departments for a severe drug-related event.
The Food and Drug Administration (FDA) today announced the addition of new risk information to the health professional labeling for Zelnorm (tegaserod maleate). Zelnorm is a prescription medication for the short-term treatment of women with irritable bowel syndrome (IBS) whose primary bowel symptom is constipation.
› Verified 6 days ago
Angela Alexander, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 450 Williams Way, Moab Regional Hospital, Moab, UT 84532 Phone: 435-719-3500 |